ADARx Pharmaceuticals, Inc.NASDAQ: ADRX

ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

· Issued by ADARx Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA (small interfering RNA) medicines, said President and CEO Zhen Li, Ph.D., will take part in a fireside chat at the UBS Global Biopharma Conference in London, UK, on Monday, November 16, at 2:00 p.m. GMT.

Key details

  • A live webcast will be available on the Events page of ADARx's investor website, and a replay will be archived on the company's website for 90 days.

6ix AI wrote this summary from the release below and checked it against the release.

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Biopharma Conference in London, UK on Monday, November 16, at 2:00 p.m. GMT.

A live webcast will be available on the Events page of ADARx’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.

About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and our two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond our named programs, we plan to continue to leverage our proprietary technologies to strategically expand our pipeline of next-generation siRNA therapeutics. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

View original source (GlobeNewswire)ADARx Pharmaceuticals, Inc. on 6ix

In the deck

Earlier from ADARx Pharmaceuticals

Later from ADARx Pharmaceuticals

All ADARx Pharmaceuticals news releases